Earnings in First Quarter 2008 at record levels: 26.5% pre-tax sales yield and 36.1% rate of growth
Berlin (euro adhoc) -
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
balance/Q1 Report
Sales by listed medical device manufacturer WORLD OF MEDICINE soared by 36.1% in the first quarter of 2008, to TE10,791. "At that level, total sales eclipsed even the normally stronger fourth quarter of the prior year," says Peter P. Wiest, CEO of WORLD OF MEDICINE. "We have reaped the benefits from the relatively recent product launches of 2007. In particular, the Medical-HD® camera for minimally invasive procedures performed extremely well in Europe." The pre-tax sales yield for the first 3 months of 2008 achieved a record value of 26.5%.
| |Q1/2008 |Q1/2007 |Change | |Sales |TE10,791 |TE7,929 |+ 36.1 % | |EBT |TE2,863 |TE1,167 |+TE1,696 | |Pre-tax sales yield|26.5 % |14.7 % |+ 80.3 % | |Earnings per share |E0.22 |E0.09 |> 100 %
Based on Management Board estimates for the remainder of the year, the opportunities in Europe and Asia must be weighed with the risk of further weakening in the US market. WORLD OF MEDICINE is therefore projecting continued steady business development, and is adhering to the annual targets set for 2008: an increase in sales equal to market growth of 7%, and a pre-tax sales yield of 11%. The Management Board, however, may pursue further investment in additional projects that hold promise for future growth opportunities.
The entire Quarterly Financial Report for the first 3 months of 2008 is available at: www.world-of-medicine.com/wsc/pdf/wom/en/qr_3monthreport_2008_wom.pdf
Today at 11:00 a.m. CET, a telephone conference on the quarterly figures is
scheduled for analysts, investors and press representatives. To participate, please contact the Company directly.
WORLD OF MEDICINE and its technologies are paving the way in Minimally Invasive Surgery - or MIS( for short. This approach includes safe and gentle surgical procedures conducted not through major incisions, but through keyhole or puncture incisions. The Company is the global market leader in a niche of this future market.
end of announcement euro adhoc
Further inquiry note:
Stefanie Gehrke
Tel.: +49 (0)30 399 81 566
E-Mail: stefanie.gehrke@womcorp.com
Branche: Pharmaceuticals
ISIN: DE0006637390
WKN: 663739
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse München / free trade